Inhaltsverzeichnis
Was ist eine lymphoproliferative Erkrankungen?
Das Autoimmun-Lymphoproliferative Syndrom ist eine angeborene chronische Erkrankung, die auf einer Fehlsteuerung des Abwehrsystems beruht. Normaler- weise haben Abwehrzellen eine be- grenzte Lebensdauer und es besteht ein Gleichgewicht zwischen Neubildung und Absterben dieser Zellen.
Was bedeutet Ptld?
Bei nierentransplantierten Patienten mit einer Posttransplantations-lymphoproliferativen Erkrankung (PTLD) ist in der Rituximab-Ära die Abschätzung des Risikos ohne Rituximab-Einsatz für Patient und Transplantat sehr wichtig, um Therapieentscheidungen treffen zu können.
What are lymphoproliferative disorders?
From Wikipedia, the free encyclopedia Lymphoproliferative disorders (LPDs) refer to a specific class of diagnoses, comprising a group of several conditions, in which lymphocytes are produced in excessive quantities. These disorders primarily present in patients who have a compromised immune system.
What is autoimmune lymphoproliferative syndrome (ALPS)?
Autoimmune lymphoproliferative syndrome (ALPS) is a type of LPD caused by a mutation in the gene that encodes for a Fas protein which is located in the long arm of chromosome 10. Males with X-linked immunodeficiency syndrome are susceptible to LPD and at risk for acquiring EBV and further development of lymphoma.
What is X-linked lymphoproliferative syndrome?
The X-linked LPD is characterized by a mutation in the X chromosome that predisposes to natural killer cell LPD and T-cell LPD. Autoimmune lymphoproliferative syndrome (ALPS) is a type of LPD caused by a mutation in the gene that encodes for a Fas protein which is located in the long arm of chromosome 10.
What is the pathophysiology of post-transplant lymphoproliferative disorder?
Monoclonal forms of post-transplant lymphoproliferative disorder can manifest as a disseminated malignant lymphoma. Generation of T-cell depletion by use of anti-T lymphocyte antibodies in the prevention/treatment of graft rejection can further increase the risk of developing the post-transplant lymphoproliferative disorder.